On the Alkermes (ALKS) Q3 2022 earnings call, CEO Richard Pops announced the approval by the Board of Directors to explore separating its commercial-stage neuroscience business and development-stage oncology business, partly due to the impacts of the Inflation Reduction Act (IRA).
All entries for: Alkermes
October 25, 2023
Alkermes
Negative Outlook
Dublin, Ireland
1,001-5,000 employees
1001-5000 employees
Disease Area: Oncology
Drug Type: Small Molecule
July 23, 2023
Alkermes
Negative Outlook
Dublin, Ireland
1,001-5,000 employees
1001-5000 employees
Disease Area: Oncology
Drug Type: Small Molecule
April 26, 2023
Alkermes
Negative Outlook
Dublin, Ireland
1,001-5,000 employees
1001-5000 employees
Disease Area: Oncology
Drug Type: Small Molecule
November 2, 2022
Alkermes
Negative Outlook
Dublin, Ireland
1,001-5,000 employees
1001-5000 employees
Disease Area: Oncology
Drug Type: Small Molecule
November 2, 2022
Alkermes
Negative Outlook
Dublin, Ireland
1,001-5,000 employees
1001-5000 employees
Impact to “Varying Degrees”: “The Inflation Reduction Act includes several provisions that will impact our business to varying degrees, including those that impose new manufacturer financial liability on all drugs in Medicare Part D beginning in 2025, allow the U.S. government to negotiate prices for some drugs covered under Medicare Part B and Part D beginning in 2026, and require companies to pay rebates to Medicare for drug prices that increase faster than inflation beginning in 2023”
Disease Area: Oncology
Drug Type: Small Molecule
